Kevin Hardy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin Hardy has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Michael Lloyd
Clinical Education Department, St. Helens and Knowsley Hospitals NHS Trust, Whiston, Merseyside, L35 5DR, UK
2 shared publications N. Furlong
St. Helens and Knowsley Hospitals NHS Trust, Whiston, Merseyside, L35 5DR, UK
2 shared publicationsS.D. Watmough
Faculty of Health and Social Care, Edge Hill University, Ormskirk, L39 4QP, UK
2 shared publicationsS.V. O'BRien
St. Helens CCG, St. Helens Chambers, St. Helens, Merseyside, WA10 1YF, UK
2 shared publications- Greg Irving
Affiliation Faculty of Health, Social Care and Medicine, Edge Hill University, Ormskirk, United Kingdom
1 shared publication Ian W Seetho
Department of Obesity and Endocrinology, University of Liverpool, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
1 shared publication
Latest Publications
- Open Access
- 18 May 2022
- Published by Elsevier in Clinical Medicine
- Vol. 22 (3) , 257-265
The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review
Background Evidence and guidelines increasingly support an individualised approach to care for people with type 2 diabetes and individualisation of glycaemic targets in response to patient factors. Methods We undertook a scoping review of the literature for evidence of factors impacting upon glycated haemoglobin target individualisation in adults with type 2 diabetes. Data were analysed thematically with the themes inductively derived from article review. Findings Evidence suggests that presence of cardiovascular disease, hypoglycaemia unawareness, severe hypoglycaemia, limited life expectancy, advanced age, long diabetes duration, frailty, cognitive impairment, disability, extensive comorbidity, diabetes distress and patient preference should inform the setting of glycaemic targets. Conclusion The management of people with diabetes is complex. In clinical practice, many patients will have a variety of factors that should be considered when personalising their care. Approaches to personalised care and glycaemic treatment targets should be undertaken as part of a shared decision-making process between physician and patient. Use of electronic records might enable greater efficiency and more widespread use of personalised care plans for people with diabetes.
- 18 May 2022
- Published by Elsevier in Clinical Medicine
- Vol. 22 (3) , 257-265
Open AccessThe individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review
Background Evidence and guidelines increasingly support an individualised approach to care for people with type 2 diabetes and individualisation of glycaemic targets in response to patient factors. Methods We undertook a scoping review of the literature for evidence of factors impacting upon glycated haemoglobin target individualisation in adults with type 2 diabetes. Data were analysed thematically with the themes inductively derived from article review. Findings Evidence suggests that presence of cardiovascular disease, hypoglycaemia unawareness, severe hypoglycaemia, limited life expectancy, advanced age, long diabetes duration, frailty, cognitive impairment, disability, extensive comorbidity, diabetes distress and patient preference should inform the setting of glycaemic targets. Conclusion The management of people with diabetes is complex. In clinical practice, many patients will have a variety of factors that should be considered when personalising their care. Approaches to personalised care and glycaemic treatment targets should be undertaken as part of a shared decision-making process between physician and patient. Use of electronic records might enable greater efficiency and more widespread use of personalised care plans for people with diabetes.
- Open Access
- 1 October 2018
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 14 (10) , 936-943
Exploring pharmacist experiences of delivering individualised prescribing error feedback in an acute hospital setting
- 1 October 2018
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 14 (10) , 936-943
Open AccessExploring pharmacist experiences of delivering individualised prescribing error feedback in an acute hospital setting
- Open Access
- 1 June 2018
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 14 (6) , 545-554
Exploring the impact of pharmacist-led feedback on prescribing behaviour: A qualitative study
- 1 June 2018
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 14 (6) , 545-554
Open AccessExploring the impact of pharmacist-led feedback on prescribing behaviour: A qualitative study
- Open Access
- 19 May 2015
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 12 (3) , 238-246
Serum urate and obstructive sleep apnoea in severe obesity
Obstructive sleep apnoea (OSA) may increase the risk of hyperuricaemia and predispose to gout. The evidence for the effects of OSA on serum urate in severe obesity is limited. This study investigated whether OSA was associated with serum urate in severe obesity and whether continuous positive airway pressure (CPAP) treatment was associated with a fall in urate. Severely obese subjects without known OSA or gout were recruited. Baseline assessments included urate, metabolic parameters, spirometry and overnight polysomnography. OSA patients were initially naive to treatment and were offered CPAP. At follow-up, change in urate was compared between CPAP-treated and non-CPAP-treated subjects. A high urate was defined as greater than the median. Logistic regression was performed to identify associations between (1) OSA and high urate at baseline and (2) use of CPAP and change in urate at follow-up. In total, 92 subjects were recruited (61 (66%) OSA and 31 (34%) non-OSA). Median urate was 345 μmol/L. OSA was associated with high urate in females at baseline after adjusting for confounders (adjusted odds ratio ORadj = 10.2; 95% CI: 1.1, 93.5). At follow-up (14 months), 58 subjects (28 on CPAP and 30 not on CPAP) were reassessed. CPAP was significantly associated with a fall to a low urate category at follow-up ( = 0.017). Regression revealed a trend for a fall in urate category in the CPAP-treated group (ORadj = 9.3; 95% CI: 0.8, 97). Serum urate is associated with OSA in severely obese females and CPAP may reduce levels in patients with OSA. There may be a need to consider and assess for OSA in obese patients with hyperuricaemia and recurrent attacks of gout.
- 19 May 2015
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 12 (3) , 238-246
Open AccessSerum urate and obstructive sleep apnoea in severe obesity
Obstructive sleep apnoea (OSA) may increase the risk of hyperuricaemia and predispose to gout. The evidence for the effects of OSA on serum urate in severe obesity is limited. This study investigated whether OSA was associated with serum urate in severe obesity and whether continuous positive airway pressure (CPAP) treatment was associated with a fall in urate. Severely obese subjects without known OSA or gout were recruited. Baseline assessments included urate, metabolic parameters, spirometry and overnight polysomnography. OSA patients were initially naive to treatment and were offered CPAP. At follow-up, change in urate was compared between CPAP-treated and non-CPAP-treated subjects. A high urate was defined as greater than the median. Logistic regression was performed to identify associations between (1) OSA and high urate at baseline and (2) use of CPAP and change in urate at follow-up. In total, 92 subjects were recruited (61 (66%) OSA and 31 (34%) non-OSA). Median urate was 345 μmol/L. OSA was associated with high urate in females at baseline after adjusting for confounders (adjusted odds ratio ORadj = 10.2; 95% CI: 1.1, 93.5). At follow-up (14 months), 58 subjects (28 on CPAP and 30 not on CPAP) were reassessed. CPAP was significantly associated with a fall to a low urate category at follow-up ( = 0.017). Regression revealed a trend for a fall in urate category in the CPAP-treated group (ORadj = 9.3; 95% CI: 0.8, 97). Serum urate is associated with OSA in severely obese females and CPAP may reduce levels in patients with OSA. There may be a need to consider and assess for OSA in obese patients with hyperuricaemia and recurrent attacks of gout.